Risk of Anaplastic Large Cell Lymphoma Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Ductal Carcinoma in Situ
Menée à l'aide de données 2000-2018 des registres américains des cancers portant sur 56 784 patientes atteintes d'un cancer du sein et ayant subi une mastectomie (âge médian : 50-54 ans ; durée médiane de suivi : 81 mois), cette étude analyse le risque de lymphome anaplasique à grandes cellules associé à une reconstruction par implant mammaire
Approximately 291 000 and 51 000 cases of breast cancer and ductal carcinoma in situ, respectively, are diagnosed in the US annually, the majority of whom undergo local curative surgery, including mastectomy with implant-based reconstruction. National and regulatory guidelines recommend that patients eligible for reconstruction be counseled on the association of breast implants with subsequent anaplastic large cell lymphoma (ALCL) as part of routine informed consent. Several series of patients with breast ALCL have found overrepresentation of patients who received reconstructive vs cosmetic surgery, leading some investigators to suggest that ALCL may be more common in women with breast cancer or a genetic risk for breast cancer. However, there is a paucity of data available to guide clinicians in counseling patients on the relative and absolute risks of ALCL after implant-based reconstruction. We previously reported that the incidence of ALCL is increasing rapidly in the US.4 Here, we report on the risk of breast ALCL in a population of women who have undergone implant reconstruction.
JAMA Network Open 2022